Alternatively spliced isoforms of tissue factor pathway inhibitor
- PMID: 20176395
- PMCID: PMC2839007
- DOI: 10.1016/j.thromres.2010.01.038
Alternatively spliced isoforms of tissue factor pathway inhibitor
Erratum in
- Thromb Res. 2010 Oct;126(4):361
Abstract
Tissue factor pathway inhibitor (TFPI) is the major regulator of tissue factor (TF)-induced coagulation. It down regulates coagulation by binding to the TF/fVIIa complex in a fXa dependent manner. It is predominantly produced by microvascular endothelial cells, though it is also found in platelets, monocytes, smooth muscle cells, and plasma. Its physiological importance is demonstrated by the embryonic lethality observed in TFPI knockout mice and by the increase in thrombotic burden that occurs when heterozygous TFPI mice are bred with mice carrying genetic risk factors for thrombotic disease, such as factor V Leiden. Multiple TFPI isoforms, termed TFPIalpha, TFPIbeta, and TFPIdelta in humans and TFPIalpha, TFPIbeta, and TFPIgamma in mice, have been described, which differ in their domain structure and method for cell surface attachment. A significant functional difference between these isoforms has yet to be described in vivo. Both human and mouse tissues produce, on average, approximately 10 times more TFPIalpha message when compared to that of TFPIbeta. Consistent with this finding, several lines of evidence suggest that TFPIalpha is the predominant protein isoform in humans. In contrast, recent work from our laboratory demonstrates that TFPIbeta is the major protein isoform produced in adult mice, suggesting that TFPI isoform production is translationally regulated.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Conflict of interest statement
AEM-research grant from Novo Nordisk
Figures


Similar articles
-
TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.J Hematol Oncol. 2013 Jan 15;6:5. doi: 10.1186/1756-8722-6-5. J Hematol Oncol. 2013. PMID: 23320987 Free PMC article.
-
Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.J Thromb Haemost. 2018 Nov;16(11):2246-2257. doi: 10.1111/jth.14288. Epub 2018 Oct 22. J Thromb Haemost. 2018. PMID: 30194803 Free PMC article.
-
Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.J Thromb Haemost. 2009 Jul;7(7):1106-13. doi: 10.1111/j.1538-7836.2009.03454.x. Epub 2009 Apr 24. J Thromb Haemost. 2009. PMID: 19422457 Free PMC article.
-
Biology of tissue factor pathway inhibitor.Blood. 2014 May 8;123(19):2934-43. doi: 10.1182/blood-2013-11-512764. Epub 2014 Mar 11. Blood. 2014. PMID: 24620349 Free PMC article. Review.
-
Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor.Curr Opin Hematol. 2013 Sep;20(5):403-9. doi: 10.1097/MOH.0b013e3283634412. Curr Opin Hematol. 2013. PMID: 23839295 Free PMC article. Review.
Cited by
-
TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.J Hematol Oncol. 2013 Jan 15;6:5. doi: 10.1186/1756-8722-6-5. J Hematol Oncol. 2013. PMID: 23320987 Free PMC article.
-
Factor V east Texas variant causes bleeding in a three-generation family.J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7. J Thromb Haemost. 2022. PMID: 34847292 Free PMC article.
-
Quantitative high-throughput profiling of snake venom gland transcriptomes and proteomes (Ovophis okinavensis and Protobothrops flavoviridis).BMC Genomics. 2013 Nov 14;14:790. doi: 10.1186/1471-2164-14-790. BMC Genomics. 2013. PMID: 24224955 Free PMC article.
-
Factor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor.Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):427-33. doi: 10.1161/ATVBAHA.111.238394. Epub 2011 Nov 23. Arterioscler Thromb Vasc Biol. 2012. PMID: 22116096 Free PMC article.
-
A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.Eur J Pharm Sci. 2019 Oct 1;138:105032. doi: 10.1016/j.ejps.2019.105032. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394258 Free PMC article.
References
-
- Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 1981;132:37–40. - PubMed
-
- Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood. 1985;66:204–212. - PubMed
-
- Engelmann B. Initiation of coagulation by tissue factor carriers in blood. Blood Cells Mol Dis. 2006;36:188–190. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous